Therapeutics News

Allergan, an AbbVie company, announced the FDA approval of the eye drop, Vuity, for the treatment of presbyopia.

Patients and providers agree that sociobehavioral factors are a key determinant of glaucoma treatment adherence, but they disagree in other areas, according to a study published in Optometry and Vision Science.

Patients with central serous chorioretinopathy may be prescribed systemic corticosteroids despite evidence showing that steroids can contribute to the disease, according to data published in Ophthalmology.

Netarsudil maintained IOP control and provided IOP-lowering efficacy when added to other treatments for patients with open-angle glaucoma or ocular hypertension, according to findings published in Current Medical Research and Opinion.

EyeMedsNow is a new browser database that allows eye care professionals and their staff to quickly access concise medication information for any eye care drug.

A pharmaceutical approach to presbyopia has clear advantages, will likely be used in combination with other approaches and may serve to drive surgical procedures.

The earlier we prepare patients for presbyopia — and reassure them that there are new treatment options on the horizon — the better.

Better patient instruction and education can help increase correct eyedrop instillation, which is affected by age, vision and upper limb mobility, according to a study published in the Journal of Glaucoma.

DENVER – Shane Kannarr, OD, spoke with Healio about Allergan’s investigational presbyopia-correcting eye drop at this year’s Optometry’s Meeting, which included several presentations focused on presbyopia.

DENVER – Walt Whitley, OD, MBA, FAAO, presented an overview at this year’s Optometry’s Meeting on the current trends in presbyopia management, including available and upcoming technology and therapeutics.